ALX Oncology Holdings, Inc. (ALXO)

Over the past six months, ALX Oncology's stock price has been influenced by clinical development and financial activities. As of April 7, 2026, the stock price was $1.83 per share, a 261.87% increase over the past year. Key events include reporting financial results, announcing an underwritten offering, and presenting new data on evorpacept's efficacy. Phase 2 trial data for evorpacept in combination with rituximab and lenalidomide in untreated indolent B-cell non-Hodgkin lymphoma were presented at ASH 2025. The company was on track to start Phase 2 ASPEN-09-Breast Cancer enrollment, with interim data anticipated in Q3 2026. Encouraging final results were announced from a Phase 1 trial evaluating evorpacept in combination with standard-of-care treatment in patients with B-cell Non-Hodgkin Lymphoma. ASPEN-03 and ASPEN-04 Phase 2 trials evaluating evorpacept with a checkpoint inhibitor for head and neck cancers did not meet primary endpoints. Analyst ratings have varied, with a consensus of "Moderate Buy" and an average 12-month price objective of $4.60.

As a clinical-stage immuno-oncology company, ALX Oncology does not have traditional product demand seasonality. However, historical stock price data has shown some seasonal tendencies, with August being the strongest month and March the weakest, although this pattern has not been consistently reliable.

ALX Oncology Holdings, Inc. is a clinical-stage immuno-oncology company focused on developing therapies that block the CD47 immune checkpoint inhibitor. Their primary product candidate, evorpacept (ALX148), is being evaluated in clinical trials for various cancers, often in combination with other anti-cancer agents. The company's pipeline also includes ALX2004, an EGFR-targeted antibody-drug conjugate in Phase 1 clinical trials for EGFR-expressing solid tumors.

ALX Oncology Holdings, Inc. is headquartered in South San Francisco, California, United States, with a primary focus on developing therapies for cancer patients within the United States.

ALX Oncology's brand reputation has been shaped by clinical trial progress and financial updates. Positive clinical trial results and biomarker validation enhance its scientific standing. The failure of the ASPEN-03 and ASPEN-04 Phase 2 trials could have a temporary negative impact. Successful financial activities, such as completing a $150 million registered offering, are viewed positively by investors. Overall, the company's reputation is closely tied to the success and progress of its clinical pipeline.

ALX Oncology Holdings Inc. has a significant institutional ownership presence, with 64 institutional owners and shareholders holding a total of 29,228,595 shares, accounting for approximately 43.01% of the company. Individuals hold about 1.29%. Major institutional shareholders include venBio Partners LLC, Redmile Group, LLC, and Millennium Management Llc.